| 23-768 |
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2024-01-17 |
Denied |
federal-circuit innovation-standard ksr-international-co-v-teleflex KSR-precedent obviousness obviousness-standard patent patent-law predictable-results reasonable-expectation-of-success |
Whether obviousness requires a showing of 'predictable' results, as this Court held in KSR, or a mere 'reasonable expectation of success,' as the Fede… |
| 23A344 |
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2023-10-17 |
Presumed Complete |
KSR-standard obviousness patent-law pharmaceutical-patents predictable-result prior-art |
Whether the Federal Circuit's obviousness analysis complies with the Supreme Court's standard in KSR International Co. v. Teleflex Inc. by requiring t… |
| 23A122 |
The TriZetto Group, Inc., et al. v. Syntel Sterling Best Shores Mauritius Limited, et al. |
Second Circuit |
2023-08-11 |
Presumed Complete |
avoided-costs circuit-split Defend-Trade-Secrets-Act remedial-damages trade-secret-misappropriation unjust-enrichment |
Whether the Defend Trade Secrets Act permits a plaintiff to recover damages for unjust enrichment, including avoided costs, independent of and in addi… |
| 22-930 |
ESET, LLC, et al. v. Finjan LLC |
Federal Circuit |
2023-03-24 |
Denied |
claim-interpretation claim-term-definition conflicting-definitions definiteness federal-circuit-precedent incorporation-by-reference inventor-lexicography patent-claim-construction patent-definiteness patentee-lexicography teva-v-sandoz |
Whether a patentee's express definition of a claim term governs over the Federal Circuit's new definition |
| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
Whether a generic drug manufacturer can be held liable for inducing infringement of a patent on a use that its FDA-approved label has expressly carved… |
| 21A677 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-05-03 |
Presumed Complete |
None |
|
| 20-1232 |
IBSA Institut Biochimique, S. A., et al. v. Teva Pharmaceuticals USA, Inc. |
Federal Circuit |
2021-03-08 |
Denied |
foreign-inventors foreign-language indefiniteness national-treatment patent patent-indefiniteness patent-priority patent-prosecution priority-date trips-agreement |
Whether, pursuant to the United States' obligations under the TRIPS Agreement, codified at 19 U.S.C. § 3511, a court construing the claims of a U.S. p… |
| 18-1508 |
Wisconsin Alumni Research Foundation v. Apple Inc. |
Federal Circuit |
2019-06-07 |
Denied |
claim-construction de-novo-review due-process JMOL jury-fact-finding jury-fact-findings jury-findings jury-trial patent-infringement procedural-due-process remand seventh-amendment standard-of-review teva-v-sandoz |
Whether the Federal Circuit can construe a claim limitation de novo, disregarding the jury's implicit fact findings on the plain and ordinary meaning … |
| 18-1289 |
Allergan, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2019-04-10 |
Denied |
blocking-patent blocking-patent-doctrine commercial-success graham-v-john-deere long-felt-need objective-indicia objective-indicia-of-non-obviousness obviousness patent-law patent-law-doctrine-of-obviousness prior-art |
Whether the Federal Circuit erred in holding that objective indicia of non-obviousness may be partially or entirely discounted where the development o… |